Tesla shed $201 billion in market value after its free cash flow turned negative, and Alphabet raised its 2026 AI capex to $205 billion.

Both reports landed the same way: badly. Today’s edition has everything that moved on one of the most expensive days the Magnificent Seven has ever had.

Switching advisors may feel like a hassle, which is why many put it off.

But the right advisor can help you make smarter decisions about retirement, taxes, and long-term wealth planning.

With SmartAsset’s no-cost tool, you can compare vetted fiduciary advisors in your area and see if it’s time for a change.

Take the Matching Quiz Now

*This example demonstrates the potential final lifetime portfolio value, accounting for estimated investment returns, tax savings and inflation over different life stages for an individual starting with $500,000 at age 45, through age 77. Under a set of core assumptions, this consumer profile is projected to have a final lifetime portfolio value of approximately $3.24 million if retaining the services of a financial advisor – not accounting for additional savings or portfolio withdrawals – versus a final estimated lifetime portfolio value of $1.56 million without the services of a financial advisor. This example is based on the valuation framework presented in SmartAsset's whitepaper "The Value of a Financial Advisor: What's It Really Worth?" (Nov. 2024). The value of professional financial advice is only an illustrative estimate and varies with each unique client's individual circumstances and portfolio composition. Carefully consider your investment objectives, risk factors, and perform your own due diligence before choosing a financial advisor.

You’re looking at one AI infrastructure stock after a bruising decline and one clinical-stage biotech trading close to its yearly high. Elite Trade Club Insider readers are seeing the conviction split beneath those charts: one executive moved millions of dollars through several trust-linked sales, while a specialist healthcare investor kept buying as the stock climbed.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Today’s filings point in opposite directions.

One company has delivered explosive revenue growth, attracted bullish analyst targets, and become a major provider of AI computing capacity. But its stock remains down more than 36% over the past year, its balance sheet is heavily leveraged, and a senior executive reported a cluster of sales worth approximately $18.78 million.

The other is a clinical-stage biotechnology company trading near the upper end of its range. RA Capital Management bought shares on three consecutive days, committing approximately $6.92 million and increasing an already enormous position.

Combined, the listed transactions represent approximately $25.7 million moving in opposite directions.

One executive is creating liquidity while the stock remains damaged.

One specialist investor is deliberately adding exposure near recent highs.

CoreWeave Chief Development Officer Brannin McBee reported several transactions dated July 20.

The listed sale lines included:

Across the three reported lines, the transactions total:

The filings appear to involve multiple trusts and ownership vehicles associated with McBee.

One accompanying filing summary focused specifically on the 55,500-share, $4.17 million tranche held through the Canis Major and Canis Minor GRATs and another irrevocable trust. Those shares were converted from Class B into Class A stock before being sold.

The broader transaction table includes two additional sale lines. Because the post-transaction ownership figures relate to different reported entities, the cleanest interpretation is a cluster of trust-linked sales rather than three duplicate entries.

The sales were conducted under a Rule 10b5-1 trading plan adopted in March 2026.

McBee also retained significant indirect exposure through several trusts, including millions of Class B shares convertible into Class A stock. This was substantial monetization, but not a complete exit.

CRWV recently traded around $82.64, above the reported sale price and up approximately 3% in after-hours trading. However, the stock remains down roughly 36% over the past year and far below its 52-week high of $153.20.

It is still above its 52-week low of $63.80.

CoreWeave continues to produce extraordinary top-line growth.

Revenue reportedly increased approximately 130% over the past 12 months as demand for specialized AI computing infrastructure remained strong. Wall Street analysts also remain broadly constructive.

Recent targets included:

Those targets imply considerable upside from the recent price.

But the company is also pursuing an exceptionally capital-intensive expansion strategy. BofA reportedly increased its fiscal 2026 capital expenditure estimate to approximately $34 billion.

CoreWeave’s reported debt-to-equity ratio of 7.39 reinforces the balance-sheet risk. Building AI data centers requires enormous upfront spending, and the company must keep adding capacity before much of that investment generates cash.

Competition is another concern. Reports that Meta may offer AI cloud capacity have raised questions about whether deep-pocketed technology companies could pressure smaller specialized providers.

The pre-arranged plan and continued indirect ownership reduce the severity of the signal.

McBee did not suddenly dispose of his entire stake after receiving unexpected bad news. The sales were scheduled in advance, involved estate-planning structures, and left him with substantial exposure.

But this is still insider selling into a weak one-year chart.

CoreWeave is not trading near its record high. The company is trying to sustain a rapid capacity build while managing heavy debt, enormous capital spending, and potential competition from technology giants.

For you, CRWV is an execution-and-financing setup.

The stock may eventually prove undervalued if AI demand remains exceptional and new capacity generates attractive returns. But the decline alone does not make the shares safe. Investors need evidence that revenue growth can turn into durable cash flow without repeated financing pressure.

If you own CRWV, track debt, capital expenditures, contracted demand, customer concentration, and how quickly new infrastructure begins contributing to earnings.

If you are considering buying the pullback, do not rely solely on analyst targets. The company must prove that its expansion creates value faster than it consumes capital.

RA Capital Management reported open-market purchases on three consecutive days.

The transactions included:

Combined, RA Capital purchased:

Following the transactions, the reported position increased to 26,529,686 shares.

The shares were held indirectly through RA Capital-affiliated investment funds. The filings also identified related parties including RA Capital Healthcare Fund, RA Capital Nexus Fund III, Peter Kolchinsky, and Rajeev Shah.

PBLS recently traded around $30.81, placing the stock approximately 9% above RA Capital’s average purchase price.

The shares are down roughly 2.5% year to date, but trade close to the upper end of their $24.66 to $34.47 52-week range.

This is the stronger conviction signal today.

RA Capital is not a corporate executive receiving stock as compensation. It is a healthcare-focused investment manager voluntarily deploying fresh capital into a clinical-stage company.

The buying also continued as the share price increased.

RA Capital paid approximately $27.28 on the first day, $29.25 on the second, and $29.77 on the third. The fund did not stop after the stock moved higher. It continued accumulating.

That pattern suggests the buyer was focused on building or expanding the position rather than waiting for the lowest possible entry.

The size of the total holding matters too. More than 26.5 million shares gives RA Capital enormous exposure to the company’s future.

This is not a symbolic purchase designed to reassure shareholders.

It is specialist capital taking substantial biotechnology risk.

Large fund buying cannot eliminate biotech risk.

Parabilis remains a clinical-stage company without positive earnings. Its valuation will ultimately depend on trial results, safety data, regulatory interactions, financing requirements, and the commercial potential of its pipeline.

A sophisticated healthcare investor can make the right scientific assessment and still experience major volatility if timelines change or clinical results disappoint.

For you, PBLS is a specialist-conviction watch.

The purchases strengthen the setup because they involved repeated open-market buying by a healthcare-focused investor with an already large position.

Aggressive investors can use RA Capital’s average cost near $28.29 as a reference point. A sustained decline below that area could indicate the market is rejecting the immediate signal. Continued strength above it would show that buyers are validating the accumulation.

More conservative investors should wait for clinical or regulatory evidence before following the fund into the trade.

Today’s filings send opposite messages.

CRWV: A senior executive reported trust-linked sales totaling approximately $18.78 million under a pre-arranged trading plan. The stock remains down roughly 36% over the past year, while the company faces heavy capital spending, leverage, and competitive risk.

PBLS: RA Capital purchased approximately $6.92 million over three consecutive days, increasing its position to more than 26.5 million shares. The specialist investor continued buying as the stock price rose.

CoreWeave is about planned executive monetization during a capital-intensive AI expansion.

Parabilis is about specialist healthcare capital deliberately increasing exposure near the upper end of the stock’s range.

The CRWV sales carry a moderate caution signal rather than evidence of a full insider exit.

The PBLS purchases carry a stronger positive signal because they involved repeated, voluntary open-market commitments.

Today’s report shows that insider conviction is not always found in the hottest narrative.

CoreWeave has the more recognizable market story. AI infrastructure demand is growing quickly, and analysts continue to publish bullish price targets. But the company also needs enormous amounts of capital, and a senior executive is using a pre-arranged plan to convert part of his exposure into cash.

Parabilis carries the less familiar and more speculative clinical story. Yet a specialist healthcare investor is increasing an already massive position and continuing to buy at progressively higher prices.

The read today: CRWV remains a high-growth AI infrastructure company that needs financing and execution proof after another insider-selling cluster. PBLS earns a place on the speculative biotech watchlist after nearly $7 million of repeated buying by a specialist investor.

If you own CoreWeave, watch whether revenue growth begins outpacing the financial burden of its capacity build. If you are watching Parabilis, track the stock against RA Capital’s average purchase price while waiting for the clinical pipeline to validate the fund’s conviction.

The crowd sees an AI cloud leader and an unfamiliar biotech chart. The filings show where one insider is creating liquidity — and where a specialist fund is still putting millions to work.

Brent hit $100.69 after Houthi militants attacked two Saudi tankers in the Red Sea, pushing the 10-year Treasury yield to its highest level in more than a year at 4.7% — mortgage rates are now expected to approach 7%.

Tesla’s Q2 free cash flow turned negative as the company burned through capital for AI and robotics, sending the stock down 14% and erasing $201 billion in market value — the largest single-session market cap loss in company history.

Alphabet raised its 2026 capex forecast to as much as $205 billion, spooking investors who are now openly asking whether the AI spending race can produce returns that justify it at this scale.

Albertsons fell 23% after cutting its full-year EPS outlook by more than 20% and missing Q1 estimates badly as higher fuel costs and cautious consumer spending ate into margins. Intel reports after the close tonight — the third major AI earnings read in two days.

Ameriprise Financial reported higher second-quarter profit as fee-generating client assets grew following a stronger market backdrop, with total assets under management, administration, and advisement reaching $1.8 trillion, up 14% from a year earlier.

Management and financial-advice fees rose 18% to $3.06 billion, while advice and wealth-management client assets climbed 15% to $1.2 trillion, keeping the story focused on asset growth and recurring fees rather than intraday share moves. 

Goldman Sachs said U.S. household equities have overtaken real estate as the top wealth driver for the first time since World War II, underscoring how closely consumer balance sheets are now tied to the market.

The bank said equity gains have been the dominant driver of household wealth accumulation and a positive force for consumer spending, while warning that heavier stock exposure also leaves households more vulnerable if valuations reset.

Intuitive Surgical used the Society of Robotic Surgery conference to outline a five-layer AI framework for surgery built around surgical data, intraoperative guidance, augmented dexterity, and longer-term supervised autonomy, while also demonstrating real-time telesurgical collaboration between California and Georgia.

The update keeps Intuitive’s robotics story tied to software, training, and connected care, with the company positioning AI to support surgeons, reduce variability, and extend specialist experience without removing surgeon control.

NovoCure used its latest presentation to show progress toward sustained profitability while highlighting stronger adoption of its Tumor Treating Fields cancer devices, including its newer pancreatic cancer product and a broader portfolio roadmap.

The update keeps NovoCure’s story focused on commercial execution, with the company moving from pure clinical expansion toward approved-product adoption, wider labels, international rollout, and cost discipline around a still-developing cancer-device business.

You followed the traditional retirement plan.

But inflation can still reduce how much your savings can buy.

The free 2026 Gold IRA Guide shows how investors can add physical gold and silver to an eligible IRA while leaving the rest of their portfolio untouched.

Claim the Free Guide Before the Dollar Loses More Buying Power.

Chevron and other PDVSA partners are racing to complete new oil and gas agreements in Venezuela before a July 28 deadline, after Caracas moved existing projects into a revised hydrocarbons law framework.

The contract shift could define how foreign oil companies operate, pay royalties, and expand production in one of the world’s largest crude reserves. For Chevron, the story is about access, permits, and operating terms, not an intraday stock reaction.

Sunrun, Eversource, National Grid, and partners will test a vehicle-to-grid service for Massachusetts residential customers, allowing eligible EV owners to send stored battery power back to the grid during peak-demand periods.

The project gives utilities another tool for flexible capacity as electricity demand rises, while drivers can earn incentives for supporting reliability. It also pushes Sunrun’s home-energy model beyond rooftop solar and batteries into parked EVs as dispatchable grid assets.

NVE Corporation [NVEC] $134.21 (+54.83%)

NVE makes spintronics-based GMR semiconductor components for magnetic sensing, defense applications, and industrial equipment. On a day when AI-heavy chip names got crushed by Alphabet’s $205B capex surprise, NVE’s non-AI-dependent semiconductor profile attracted a flight-to-quality bid within the sector.

At a $640.68 million market cap with a 4.61% dividend yield and positive EPS, this is the kind of quality name that outperforms when the AI narrative stumbles.

Paranovus Entertainment Technology [PAVS] $5.91 (+52.32%)

Paranovus is a health technology company running at 375x average daily volume today, a signal of extraordinary speculative activity in a name with $9.02 million in market cap.

The stock ran from near $4 to above $8 in a session where energy and defensive names attracted flows away from the battered tech sector. When thin-float names move at this velocity, the mechanics are usually running ahead of any fundamental story.

Sky Quarry [SKYQ] $5.64 (+36.56%)

Sky Quarry extracts crude oil from oil sands and tar sands deposits — assets that are economically marginal at $60 per barrel and commercially compelling at $100 per barrel.

Today, Brent crossed $100 a barrel, and Sky Quarry is one of the most direct beneficiaries. The math on oil sands changes dramatically at triple-digit oil prices, and the market priced that in quickly.

Liberty Energy [LBRT] $19.62 (-21.96%)

Liberty Energy provides hydraulic fracturing services for oil and gas producers and fell 21% on the same day oil hit $100, which feels paradoxical until you look at the other side of the trade.

At $100 oil, producers face rising input costs and demand destruction fears, which creates hesitation around new drilling commitments. Fracking service companies like Liberty get caught between today’s elevated commodity price and tomorrow’s potential activity slowdown. Buy rated at $3.23 billion.

Shutterstock [SSTK] $5.76 (-21.95%)

Shutterstock’s failed Getty Images merger continues to haunt the company as it navigates what it looks like as a standalone business without that deal’s scale.

The stock is now trading at $5.76 with an 18.7% dividend yield — a yield that high is often the market’s way of saying it doesn’t believe the payout is sustainable. At $202 million in market cap, the stock has fallen nearly 80% from its deal-announcement highs.

Albertsons [ACI] $11.44 (-21.64%)

Albertsons reported Q1 adjusted EPS of $0.42 against a $0.54 estimate — a 22% miss — and cut its full-year EPS outlook from $2.22-$2.32 to $1.75-$1.85, slashing expected earnings by more than 20%. The CFO announced her retirement alongside the results.

Higher fuel costs from $100 oil are eating into grocery margins, and the consumer is tightening up on food spending. Wells Fargo downgraded immediately and cut its target to $11. Buy rated at $5.49 billion.

When Trump signed Executive Order 14330, he quietly opened a $216 trillion opportunity to regular Americans.

And Trump collects up to $250,000 a month through a little known fund directly tied to this boom.

Now you can access it for less than $20.

See how to get the full story here

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.